eFFECTOR Therapeutics, Inc., a biopharmaceutical company based in Delaware, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 30, 2024, to deregister all unsold securities previously registered under two Registration Statements. The affected Registration Statements are No. 333-267221, initially filed on September 1, 2022, and No. 333-272738, filed on June 16, 2023. This move is in line with the company's undertakings to remove from registration any securities that remain unsold at the termination of the offering. The deregistration indicates that eFFECTOR Therapeutics, which is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company, will not proceed with the sale of these securities to the public. The amendment was signed by Craig Jalbert, Chief Executive Officer of eFFECTOR Therapeutics.

eFFECTOR Therapeutics, Inc., a biopharmaceutical company based in Delaware, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 30, 2024, to deregister all unsold securities previously registered under two Registration Statements. The affected Registration Statements are No. 333-267221, initially filed on September 1, 2022, and No. 333-272738, filed on June 16, 2023. This move is in line with the company's undertakings to remove from registration any securities that remain unsold at the termination of the offering. The deregistration indicates that eFFECTOR Therapeutics, which is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company, will not proceed with the sale of these securities to the public. The amendment was signed by Craig Jalbert, Chief Executive Officer of eFFECTOR Therapeutics.